Hofseth BioCare ASA

Oslo Stock Exchange HBC.OL

Hofseth BioCare ASA Net Income Margin for the year ending December 31, 2023: -54.74%

Hofseth BioCare ASA Net Income Margin is -54.74% for the year ending December 31, 2023, a 52.01% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Hofseth BioCare ASA Net Income Margin for the year ending December 31, 2022 was -114.06%, a 20.97% change year over year.
Hofseth BioCare ASA Net Income Margin for the year ending December 31, 2021 was -144.34%, a 2.09% change year over year.
Hofseth BioCare ASA Net Income Margin for the year ending December 31, 2020 was -147.42%, a -12.00% change year over year.
Hofseth BioCare ASA Net Income Margin for the year ending December 31, 2019 was -131.62%, a 5.69% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

Oslo Stock Exchange: HBC.OL

Hofseth BioCare ASA

CEO	Mr. Jon Olav Odegard
IPO Date	Dec. 2, 2011
Location	Norway
Headquarters	Kipervikgata 13
Employees	69
Sector	Consumers Staples
Industries Pet Food Baby & Childcare Biotechnology Cleaning Supplies Cosmetics Frozen Foods Personal Care Plastics

Description

Hofseth BioCare ASA engages in providing value added biomarine ingredients for human and animal applications in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol and cardiovascular function; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; CalGo, a marine calcium powder produced to support cartilage function and joint health; CollaGo, a collagen peptide powder to enhance the beauty of hair, skin, and nails; and PetGo, a non-soluble protein. The company distributes its products through distributors, agents, and its own sales force. It has a research agreement with Stanford University School of Medicine for pre-clinical and clinical research on necrotizing enterocolitis and irritable bowel syndrome. The company was founded in 2000 and is headquartered in Ålesund, Norway.

Key trends

Past 5 years